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Several 5-substituted 2-pyrimidinone 2'-deoxyribonucleoside (PdR) analogs were examined for their anti-
herpes simplex virus (HSV) activity in cell culture. The order of potency of their antiviral activities against HSV
type 1 (HSV-1) and HSV-2 was iodo PdR - ethynyl PdR propynyl PdR. The antiviral action of iodo PdR
is dependent on the ability of HSV to induce virus-specified thymidine kinase in infected cells. Several HSV-1
variants with altered thymidine kinase changed their sensitivity to iodo PdR, whereas HSV-1 variants with
altered DNA polymerase were as sensitive as the parental virus to iodo PdR. Continuous presence of iodo PdR
for more than one virus replication cycle was required for optimal antiviral activity. Iodo PdR (100 ,uM) had
no activity against Epstein-Barr virus DNA replication in P3HR-1 cells. With an oral, an intraperitoneal, or a
subcutaneous route of injection, iodo PdR administered twice a day for 2.5 days could prevent the death of mice
infected with HSV-2. This in vivo activity is unlikely to be related to the potential conversion of iodo PdR to
iododeoxyuridine, since iodo PdR is not a substrate of xanthine oxidase.
Herpes simplex virus types 1 and 2 (HSV-1 and -2) are
recognized as inducers of type-specific thymidine kinase
(TK) in virus-infected cells. These viral TKs have a broader
spectrum of substrate specificity than host TK (5, 7). The
development of compounds based on the unique properties
of HSV TK has already been proposed (6), and several
nucleoside analogs were developed and used as anti-HSV
compounds in the clinic. Although virus TK is involved in
the selectivity of these anti-HSV nucleosides, it should be
noted that the metabolisms and mechanisms of action could
be quite different. The synthesis of new anti-HSV nucleoside
analogs based on viral TK with different mechanisms of
action is continually being pursued by many laboratories.
This communication reports on the anti-HSV activity of a
newly synthesized 2-pyrimidinone nucleoside (Fig. 1) in both
cell culture and mice. A preliminary report on the activity of
5-iodo-2-pyrimidinone 2'-deoxyribonucleoside (IPdR) was
published previously (16).
MATERIALS AND METHODS
Sodium n-butyrate, 12-O-tetradecanoylphorbol 13-ace-
tate, xanthine, and N,N-dimethylaniline were purchased
from Sigma Chemical Co., St. Louis, Mo. [Q_-32P]dCTP was
purchased from ICN Pharmaceuticals Inc., Irvine, Calif.
Nitrocellulose was from Schleicher & Schuell, Inc., Keene,
N.H. The Random Primed DNA Labeling Kit, 3-methyl-
2-benzothiazolinone hydrazone hydrochloride, peroxidase,
and xanthine oxidase were purchased from Boehringer
Mannheim Biochemicals, Indianapolis, Ind. The 5-substi-
tuted 2-pyrimidinone 2'-deoxyribonucleoside (PdR) analogs,
iodo PdR (IPdR), ethynyl PdR (EPdR), propynyl PdR
(PPdR), and methyl PdR (MPdR), were made in the labora-
tory of Thomas Bardos, Department of Medicinal Chemis-
try, State University of New York, Buffalo (16).
Animal studies. Swiss Webster female mice (Hilltop Lab-
oratories, Chatsworth, Calif.), 6 to 8 weeks old and weighing
* Corresponding author.
approximately 20 g, were infected intraperitoneally on day 0
with 5 x 105 PFU or 1 x 106 PFU of HSV-2 (strain 333). The
drugs were administered intraperitoneally, subcutaneously,
or orally once a day for 5 days or twice daily (at 12-h
intervals) for 2.5 days beginning 24 or 72 h postinfection.
Mean body weight determinations of drug-treated and con-
trol animals were made during the treatment period as
an indicator of sublethal toxicity. Deaths were recorded
through day 45.
Cells. All cells were cultured in RPMI 1640 medium
supplemented with either 10% (P3HR-1) or 5% (HeLa and
Vero) fetal bovine serum and 100 ,ug of kanamycin per ml.
The cells were maintained in a humidified atmosphere at 5%
CO2 at 37°C.
Virus. Phosphonoformic acid (PFA)-resistant HSV-1 mu-
tants were developed as previously described (2) in the
laboratory of Y.-C. Cheng (Department of Pharmacology,
University of North Carolina, Chapel Hill). HSV-1 variants
with an altered TK were a gift from H. J. Field (Department
of Pathology, Cambridge University, Cambridge, United
Kingdom) and were developed as previously described (11).
The HSV-1 variant MDK was a gift from S. Kit, College of
Medicine, Baylor University, Houston, Tex. (10).
All the viruses (HSV-2 strain 333 and all HSV-1 strains)
were maintained as previously described (8), with the excep-
tion that Vero cells were used instead of CV-1 cells and the
multiplicity of infection was 0.01 PFU per cell.
In vitro experiments. For HSV studies, a monolayer of
HeLa S3 cells was infected with HSV at a multiplicity of 3
PFU per cell. After 1 h of adsorption, the inoculum was
removed, and medium was added with or without the
indicated concentrations of IPdR (see legend to Fig. 2). The
total incubation time was 24 h, unless otherwise indicated.
To determine the reversibility of the antiviral activity of
IPdR, the drug was removed 12 h postinfection and replaced
with fresh drug-free medium. The cells were incubated for a
total of 36 h postinfection. At the end of incubation, the
flasks were stored at -70°C until virus titration. The proce-
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FIG. 1. Structures of 5-substituted 2-pyrimidinone analogs. Ab-
breviations: MPdR, 5-methyl-2-pyrimidinone; IPdR, 5-iodo-2-py-
rimidinone; EPdR, 5-ethynyl-2-pyrimidinone; and PPdR, 5-propy-
nyl-2-pyrimidinone.
dure for virus titration was as described previously (8), with
the exception that Vero cells were used instead of CV-1
cells.
The induction of Epstein-Barr virus (EBV) was performed
as previously described (13), except with P3HR-1 cells
instead of Raji cells. Briefly, P3HR-1 cells were plated at a
density of 5 x 105 cells per ml and incubated for 48 h at 37°C
in the presence of 4 mM sodium n-butyrate and 50 nM
12-O-tetradecanoylphorbol 13-acetate with or without 100
,uM IPdR. EBV DNA synthesis was analyzed by in situ
discontinuous agarose gel electrophoresis as previously de-
scribed (13), with the exception that only two different
percentages of agarose were used. The body of the gel was
prepared by using 0.8% agarose, and the well area was
prepared by using 0.4% agarose. The transfer of DNA to a
nitrocellulose filter was accomplished by use of a vacuum
blot apparatus (American Bionetics, Inc., Hayward, Calif.)
according to the instructions of the manufacturer. Hybrid-
ization was then performed with the EcoRI C fragment of
EBV labeled with [32P]dCTP (labeling was done with a
Random Primed DNA Labeling Kit [Boehringer Mannheim]
according to the instructions of the manufacturer).
Xanthine oxidase assay. A colorimetric method for the
assay of xanthine oxidase activity based on the production of
hydrogen peroxide (H202) was used to determine the ability
of xanthine oxidase to oxidize IPdR. The assay was per-
formed as described previously (18). Briefly, various con-
centrations of xanthine or IPdR were incubated with 0.1 M
phosphate buffer (pH 8.5) containing 1 mM sodium azide for
5 min at 37°C. Xanthine oxidase was then added to the
substrate mixture, and incubation continued at 37°C. The
oxidation reaction, which produces an oxidized product and
H202, was stopped at the indicated times (see Fig. 4) with
addition of 0.2 M citric acid. A color reagent (9.6 mg of
3-methyl-2-benzothiazolinone hydrazone hydrochloride, 0.3
ml of N,N-dimethylaniline, and 400 U of peroxidase dis-
solved in 100 ml of 0.2 M citrate-phosphate buffer [pH 3.5])
was then added to the samples. A coupling reaction between
3-methyl-2-benzothiazolinone hydrazone hydrochloride and
N,N-dimethylaniline with H202 took place, producing an
indamine dye and water. The production of the dye was then
read at A60.
RESULTS
Several of the pyrimidinone analogs were screened for
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FIG. 2. Antiviral activity of 2-pyrimidinone nucleoside analogs
in vitro. HeLa S3 cells infected with either HSV-1 or HSV-2 were
treated with 10, 25, or 100 ,uM IPdR for 24 h. Virus production (in
PFU per milliliter) was assessed by a virus yield assay and is
expressed as a percentage of the no-drug control. The determina-
tions represent the average of duplicate samples from the same
experiment.
analogs was IPdR = EPdR > PPdR > MPdR for HSV-1 and
IPdR - EPdR PPdR > MPdR for HSV-2 (Fig. 2). IPdR
showed significant anti-HSV activity with 50% inhibitory
concentrations of 13 and 19 ,uM against HSV-1 and HSV-2,
respectively. In addition, the cytotoxicity of IPdR in unin-
fected HeLa S3 cells was 11% at 200 ,uM.
The antiviral activity of IPdR against various HSV-1
mutants was also determined. The results are shown in Table
1. IPdR had a much reduced antiviral effect against HSV-1
variants that are either deficient in or have an altered
HSV-specified TK. However, the antiviral activity of IPdR
was not reduced in variants which are PFA and 9-(2-
hydroxyethoxymethyl)guanine (ACV) resistant by means of
an altered DNA polymerase. This result was not unex-
pected, since the antiviral activity of IPdR is dependent on
the HSV-specified TK.
The ability of HSV-2 replication (activity) to recover after
removal of IPdR from the cell cultures was examined and is
shown in Fig. 3. While the continued presence of IPdR was
not required for antiviral activity, the optimal antiviral
activity was obtained when IPdR was present for more than
one virus replication cycle. By comparison, the antiviral
action of (E)-5-(2-bromovinyl)-2-deoxyuridine (BVDU)
TABLE 1. Antiviral activity of IPdR against HSV-1 variants
HSV-1l strain Description of strain % PFUb
SCS Parental strain 1.2
S1 TK altered; BVDU and ACV resistant 47
B3 TK altered; BVDU resistant 95
Tr7 TK altered; ACV resistant 19
MDK (2006) TK deficient 56
KOS Parental strain 0.4
PFArla DNA POLC altered; PFA and ACV 0.4
resistant
PFAr3b DNA POL altered; PFA and ACV 0.5
resistant
PFAr5a DNA POL altered; PFA and ACV 0.2
resistant
"For the origin of virus strains, see Materials and Methods.
b The sensitivity of the viruses in the presence of 50 FM IPdR for 24 h was
determined by a virus yield assay. For virus yield assay details, see reference
8. Data are expressed in percent PFU relative to a no-drug control.
' DNA POL, DNA polymerase.
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FIG. 3. Recovery of HSV-2 activity after removal of IPdR from cell culture. HeLa S3 cells infected with HSV-2 were incubated with or
without 100 ,uM IPdR. At 12 h postinfection, IPdR was removed from one set of infected cells and replaced with medium without IPdR. Total
incubation time was 36 h. Virus production (PFU per milliliter) was assessed by a virus yield assay. The determinations represent the average
of duplicate samples from the same experiment. BVDU, (E)-5-(2-Bromovinyl)-2-deoxyuridine.
against HSV-2 was not reversible after removal. The irre-
versible antiviral action may be due to the incorporation of
BVDU into the viral DNA (1, 12).
An in situ, discontinuous agarose gel was used to examine
the effect of IPdR on the synthesis of EBV DNA (for details
see Materials and Methods). The induction of EBV-specified
DNA was not detectably affected in the presence of 100 pFM
IPdR (results not shown). This lack of activity against EBV
may be due to the absence of phosphorylation of IPdR in
EBV-containing cells.
The antiviral activity of IPdR was also studied in vivo
(Table 2). A dose-dependent response to orally administered
IPdR was observed. Orally administered IPdR (100 mg/kg)
was comparable to orally administered 9-(1,3-dihydroxy-
2-propoxymethyl)guanine (DHPG) (40 mg/kg) (for discus-
sion of antiviral activity of DHPG see reference 17). How-
ever, regardless of the route of administration, IPdR could
significantly increase the life span of mice infected with
HSV-2 when given twice a day for 2.5 days. Also, the same
potent antiviral effect of IPdR was observed when IPdR was
administered to the animals at the onset or well after the
initiation of HSV-2 infection. In addition, IPdR was still
effective when the inoculum dose of HSV-2 was increased to
106 PFU. No significant toxicity as determined by weight
loss was observed for any of the administered compounds.
The potent antiviral activity in vivo and the pyrimidinone
structure of IPdR led us to study the possible oxidation of
IPdR to iododeoxyuridine (IUdR), another potent antiviral
nucleoside analog (14). A likely enzyme for this oxidation
reaction is xanthine oxidase. Xanthine oxidase is known to
have a low substrate specificity and is able to oxidize
xanthine, purines, and aldehydes (3, 4, 15). To determine if
IPdR could be oxidized to IUdR by xanthine oxidase, 1 mM
or 300 puM IPdR was added as a substrate to a colorimetric
xanthine oxidase assay. Xanthine oxidase was added to a
concentration of 10 x 1G-3 or 100 x 10-3 U per assay. The
oxidation of IPdR was assayed over a period of 2 h (Fig. 4).
The production of H202 from the oxidation of IPdR could
not be detected even after 2 h, whereas in the same experi-
ment, the oxidation of xanthine could be detected very soon
after the addition of xanthine oxidase and the oxidation
reaction was completed by 3 min. Even with a fivefold-lower
concentration of xanthine oxidase, the oxidation of xanthine
was completed within 10 min.
DISCUSSION
The 5-substituted 2-pyrimidinone 2'-deoxyribonucleoside
analogs, which share a common structure with thymidine
TABLE 2. Antiviral activity of IPdR in HSV-2
(333)-infected mice'
No. of Mean
Drug (mg/kg) Route' Schedule' survivors survival time %
tota()d (days) ILSftotal(9,0 (-- SD)e
Control i.p. 1 x 5 1/10 (10) 9.6 ± 1.1
EPdR (100) i.p. 1 x 5 1/5 (20) 9.0 ± 0.8 94
lPdR (100) i.p. 1 x 5 7/10 (70) 12.0 ± 4.4 129
Control s.c. 1 x 5 0/5 (0) 9.4 + 1.1
IPdR (100) s.c. 1 x 5 2/5 (40) 12.3 ± 1.2 131
Control i.p. 2 x 2.5 0/10 (0) 9.3 + 1.1
IPdR (10) i.p. 2 x 2.5 0/5 (0) 12.8 ± 3.6 133
IPdR (40) i.p. 2 x 2.5 2/5 (40) 10.0 ± 1.0 108
IPdR (100) i.p. 2 x 2.5 6/10 (60) 12.5 ± 1.3 135
Control Oral 2 x 2.5 4/20 (20) 10.6 ± 2.1
IPdR (10) Oral 2 x 2.5 0/5 (0) 12.8 ± 3.6 123
IPdR (40) Oral 2 x 2.5 2/5 (40) 10.0 ± 1.0 94
IPdR (100) Oral 2 x 2.5 20/20 (100) >45
DHPG (40) Oral 2 x 2.5 20/20 (100) >45
Controlg Oral 2 x 2.5 0/5 (0) 10.0 ± 1.2
IPdR (100) Oral 2 x 2.5 4/5 (80) 14.0 140
DHPG (40) Oral 2 x 2.5 2/5 (40) 20.0 t 7.0 200
Controlh Oral 2 x 2.5 0/5 (0) 9.8 ± 1.3
IPdR (100) Oral 2 x 2.5 5/5 (100) >45
DHPG (40) Oral 2 x 2.5 5/5 (100) >45
"Mice were infected intraperitoneally with 5 x 105 PFU of HSV-2 (333).
i.p., Intraperitoneal; s.c., subcutaneous.
The number of daily doses of drug times the number of days treatment was
given.
d Percent survival is the number of mice alive at 45 days over the total
number per group.
e The average day of death of the mice in the experimental group.
f ILS, Increased life span of treated mice (increased over mean life span of
untreated mice) in percent, excluding 45-day survivors.
g Mice in this experiment were inoculated with 1 x 106 PFU instead of
5 x 105 PFU.
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FIG. 4. Oxidation of IPdR by xanthine oxidase. IPdR (1 mM or 300 ,uM) or xanthine (100 ,uM) was incubated with xanthine oxidase.
Hydrogen peroxide (H202) was measured over the course of 120 min by the procedure described in Materials and Methods.
and deoxycytidine, were strategically developed as anti-
HSV agents (16). The strategy of development was based on
the hypothesis that nucleosides without an amino group or
oxygen at position 4 could be utilized as substrates by viral
TK, but not by cellular nucleoside kinases. Therefore,
pyrimidinone analogs could be selectively phosphorylated
by HSV-specified TK. Several of the pyrimidinone analogs
were screened for antiviral activity in cell culture. Even
though EPdR had antiviral activity equal to or better than
that of IPdR in vitro, IPdR was chosen for further study,
since IPdR in vivo is much more active than EPdR (Table 2).
The dependence of the antiviral activity of IPdR on the
HSV-specified TK is evident by its reduced activity in
HSV-1 variants with modified TK but not in variants with
altered DNA polymerase.
The antiviral activity of IPdR in vivo can be maintained
when the agent is given orally but probably is not maintained
as a result of the agent being metabolized to IUdR by
xanthine oxidase. The sensitivity of the xanthine oxidase
assay is such that if in 120 min 4,000-fold less of the end
product (H202) was formed, it would still be detectable.
Thus, the sensitivity of the assay should allow the detection
of IPdR product conversion if it can be utilized by xanthine
oxidase as a substrate. Although we cannot rule out that
there are other enzymes capable of converting IPdR to IUdR
in mice, it can be concluded that IPdR is not a substrate of
xanthine oxidase. In addition, IUdR has been shown to be
toxic (14), whereas IPdR has no toxicity at effective dosages
in vivo. In view of that, it is unlikely that the observed
anti-HSV-2 activity in mice is the result of conversion of
IPdR to IUdR.
In conclusion, we have shown that the pyrimidinone
nucleoside analog IPdR has very potent antiviral activity
against HSV-1 and HSV-2 in vitro and against HSV-2 in
vivo. The antiviral selectivity and activity of IPdR is depen-
dent on the HSV-specified TK. In view of the substrate
specificity of nucleoside monophosphate kinases and DNA
polymerase, this compound may not be easily incorporated
into DNA, which is the key mechanism of action of other
viral-TK-dependent antiviral compounds (9, 17). It is con-
ceivable that the active metabolite may be the monophos-
phate nucleoside and that the mechanism of action is quite
different from those of other antiviral compounds. The
metabolism and mechanism of action of IPdR are being
investigated.
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